Loading
Everything OnCo dates to 2018: 629 entries, 171 papers, 165 papers listed on people's pages, 113 landmarks and 65 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
629 dated entries in OnCo fall in 2018: 171 papers, 165 papers listed on people's pages, 113 landmarks, 65 trials reported, 55 approvals, 26 regulatory events, 13 companies founded, 10 technologies, 3 journals founded, 3 laws and regulations, 3 guideline changes and 2 financing rounds.
Of those, 24 to the day, 5 to the month and 600 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued...
High-risk mHSPC (LATITUDE)
Uncommon EGFR mutations (S768I, L861Q, G719X)
Untreated ALK-positive advanced non-small-cell lung cancer. TA536, published 8 August 2018, within its marketing authorisation subject to the commercial arrangement (ALEX).
Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)
Non-metastatic CRPC (SPARTAN)
Newly diagnosed low-risk APL with tretinoin
ALL in patients 1 month-21 years (calaspargase pegol)
Locally advanced or metastatic non-small-cell lung cancer after chemotherapy. TA520, published 16 May 2018, stopped at 2 years of uninterrupted treatment or earlier on progression...
First-line stage III-IV ovarian cancer after surgery
BRAF V600E/K melanoma with encorafenib
Olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
First-line stage III/IV Hodgkin lymphoma with AVD
ALK-positive NSCLC
X-linked hypophosphataemia; FGF23-related hypophosphataemia in tumour-induced osteomalacia (phosphaturic mesenchymal tumours not curatively resectable or localisable).
Advanced cutaneous squamous cell carcinoma
Untreated ALK-positive advanced non-small-cell lung cancer. TA500, published 24 January 2018, with the discount agreed in the patient access scheme (ASCEND-4).
MRD in bone marrow, B-cell acute lymphoblastic leukaemia and multiple myeloma (De Novo)
First-line metastatic NSCLC with EGFR exon 19 del or L858R
Paediatric Ph+ ALL with chemotherapy
Unresectable stage III NSCLC after chemoradiation
Relapsed/refractory CLL/SLL after ≥2 prior therapies; FL (withdrawn 2021)
With pomalidomide-dexamethasone after ≥2 therapies
Primary haemophagocytic lymphohistiocytosis, refractory, recurrent or progressive, or intolerant of conventional therapy
BRAF V600E-mutant metastatic colorectal cancer, with cetuximab. Braftovi marketing authorisation issued 19 September 2018; the EMA product page lists metastatic colorectal cancer w...
BRAF V600 melanoma with binimetinib
Non-metastatic CRPC
Chronic immune thrombocytopenia in adults with insufficient response to a previous treatment
Refractory mCRC (FRESCO)
Relapsed or refractory FLT3-mutated AML
Newly diagnosed AML in adults ≥75 or unfit for intensive chemotherapy, with low-dose cytarabine
Relapsed/refractory IDH1-mutated AML
Solid tumours with NTRK gene fusion without known acquired resistance mutation, metastatic or unresectable, adults and children
First-line unresectable HCC
ALK+ NSCLC after prior ALK TKI
SSTR+ GEP-NETs
Prevention of chemotherapy-induced neutropenia in non-myeloid cancers
MF/SS after ≥1 systemic therapy
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue. Withdrawn from market 2023
gBRCA HER2- metastatic breast cancer
First-line EGFR-mutant NSCLC
First biosimilars (Fulphila, Udenyca); further biosimilars 2019 onwards
Untreated PD-L1-positive metastatic non-small-cell lung cancer with a tumour proportion score of 50 percent or more and no EGFR or ALK alteration.
510(k) clearance: AI detection for digital breast tomosynthesis (first for 3D mammography)
HER2+ advanced breast cancer with capecitabine
Paroxysmal nocturnal haemoglobinuria. Later extended to atypical haemolytic uraemic syndrome and generalised myasthenia gravis
Maintenance in recurrent ovarian cancer after platinum response (now BRCA-mutated only)
Relapsed or refractory classical Hodgkin lymphoma after two or more lines
Blastic plasmacytoid dendritic cell neoplasm, adults and children ≥2
gBRCA HER2- locally advanced/metastatic breast cancer
Relapsed/refractory DLBCL
Melanoma (first of many indications)
510(k) clearance, 2D mammography
AML with azacitidine/decitabine/LDAC in unfit patients
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
gBRCA HER2-negative metastatic breast cancer (OlympiAD)
SSTR+ gastroenteropancreatic NETs (NETTER-1)
Unresectable stage III NSCLC after chemoradiation (PACIFIC)
With aromatase inhibitor first line (MONARCH 3)
Breakthrough Therapy designation
First-line stage III/IV Hodgkin lymphoma with AVD (ECHELON-1)
MRD-positive B-ALL: first approval based on MRD
Recurrent ovarian maintenance (ARIEL3)
With nivolumab in RCC
With ipilimumab, intermediate/poor-risk RCC (CheckMate 214)
First-line EGFR-mutant NSCLC (FLAURA)
FDA Breakthrough Device designation
TAILORx results define recurrence score ≤25 as chemotherapy-sparing
CLL/SLL with rituximab (MURANO)
First-line ovarian cancer (GOG-0218)
Encorafenib + binimetinib approved for BRAF V600 melanoma
BRAF V600 melanoma with binimetinib (COLUMBUS)
Pre/perimenopausal women and with fulvestrant (MONALEESA-7/-3)
First IDH1 inhibitor
Advanced cutaneous squamous cell carcinoma: first systemic therapy approved for CSCC
gBRCA HER2-negative locally advanced/metastatic breast cancer (EMBRACA)
ALK+ NSCLC after prior ALK TKIs (accelerated)
First-line CD30+ peripheral T-cell lymphoma with CHP (ECHELON-2)
Newly diagnosed AML in unfit patients with azacitidine/decitabine/LDAC (accelerated)
ADMIRAL interim; full OS data 2019
First-line maintenance in BRCA-mutated ovarian cancer (SOLO-1)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
China, scheme.
United States, statute.
United Kingdom, statute.
The dated NCCN and ESMO versions in the guideline history, with the rows each one added, removed or recategorised.
1 row added. Anchored to FDA approval of abiraterone for high-risk metastatic hormone-sensitive disease, February 2018 (LATITUDE, STAMPEDE).
1 row added. Anchored to FDA approval of adjuvant dabrafenib plus trametinib, April 2018 (COMBI-AD), following adjuvant nivolumab (December 2017).
1 row recategorised. Anchored to FDA approval of first-line osimertinib, April 2018 (FLAURA).
The year reported on trial records, with the headline result the record gives.
Median metastasis-free survival 40.5 months with apalutamide added to androgen deprivation against 16.2 months with placebo (hazard ratio 0.28, 95 percent confidence interval 0.23...
Median progression-free survival 24.0 vs 11.1 months (hazard ratio 0.48, blinded independent review, final analysis).
OS 9.6 vs 6.3 months, HR 0.68.
All-cause mortality HR 1.14; cancer mortality HR 1.31; no cancer prevention.
Carboplatin added to neoadjuvant paclitaxel raised the pathological complete response rate and improved event-free survival in triple-negative breast cancer; veliparib added nothin...
Sunitinib alone was non-inferior to cytoreductive nephrectomy plus sunitinib for overall survival in intermediate- and poor-risk metastatic clear cell renal cell carcinoma.
OS 10.2 vs 8.0 months, HR 0.76.
dMMR nivolumab plus ipilimumab cohort: objective response 55 percent, twelve-month overall survival 85 percent. MSS cohort with cobimetinib: objective response 3 percent.
Intracranial clinical benefit 57% and complete response 26% in the asymptomatic cohort.
8-year OS HR 0.72 (ITT), 0.69 (intermediate/poor risk).
Nephrectomy alone was adequate for very low-risk favourable-histology Wilms tumour, and intensified therapy improved outcomes for tumours with 1p and 16q loss of heterozygosity.
Overall 4-year EFS 85.4% and OS 95.6% (vs 72.5% and 84.0% in NWTS-5); 4-year EFS 90.2% for LOH 1p/16q stage III-IV with augmented therapy.
PFS 14.9 vs 7.3 months (HR 0.54); median OS 33.6 months.
OS 9.56 vs 5.95 months, HR 0.69; 5-year OS 18% vs 8%.
A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.
ORR 81%; 12-month OS 76%; 5-year OS 55%.
PFS 8.6 vs 5.6 months, HR 0.54; OS HR 0.85, not significant.
Objective response 47% in the metastatic group; 46% in the pooled analysis of 193 patients with 16% complete responses.
Imatinib with BFM chemotherapy gave four-year disease-free survival of 72.9 percent against 61.7 percent without imatinib in good-risk children (not significant); continuous imatin...
Median progression-free survival 18.9 vs 10.2 months (hazard ratio 0.46); median overall survival 38.6 vs 31.8 months (hazard ratio 0.80).
Median overall survival 9.3 against 6.6 months (hazard ratio 0.65).
Hyperfractionated cyclophosphamide did not improve remission, event-free or overall survival; five-year event-free survival was 52.2 percent overall and 55.7 percent under age 55 a...
Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.
Ten-year disease-free survival 76.8 percent without axillary clearance against 74.9 percent with it (hazard ratio 0.85); lymphoedema 4 against 13 percent.
Three months non-inferior to six for CAPOX and for low-risk (T1-3 N1) disease; six months better for T4 or N2.
PFS HR 0.62 in PD-L1+; approval withdrawn 2021 (US).
OS 12.3 vs 10.3 months, HR 0.70.
Median progression-free survival 8.3 against 6.8 months (hazard ratio 0.62) and significantly longer overall survival for atezolizumab with bevacizumab and chemotherapy over bevaci...
Two-year local regrowth 25.2 percent, 97 percent of it in the bowel wall; five-year overall survival 85 percent, disease-specific survival 94 percent.
iDFS HR 0.50; OS HR 0.66.
Pembrolizumab plus carboplatin and a taxane improved overall and progression-free survival over chemotherapy alone across PD-L1 levels; approved in October 2018.
Pathological complete response 44.4% (T-DM1 + pertuzumab) vs 55.7% (TCHP); more locoregional progression before surgery with T-DM1.
4.5-year DFS 86.0% vs 96.5%; death HR 6.00 with MIS.
At two years, autologous reconstruction gave higher satisfaction with breasts (7.94 points on the BREAST-Q), psychosocial and sexual wellbeing than implants, but roughly double the...
Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.
Venetoclax plus rituximab greatly lengthened progression-free survival compared with bendamustine-rituximab, with high rates of undetectable minimal residual disease; approved in J...
Response in 23 percent of the first 230 patients; trastuzumab plus pertuzumab gave a 32 percent response rate in HER2-amplified colorectal cancer, now a guideline option; atezolizu...
ORR 75% by independent review in the first 55 pooled patients across 17 tumour types.
OS 45.7 vs 33.9 months (HR 0.67).
Tumour-free survival at five years 80.5 per cent with imiquimod, 70.0 per cent with fluorouracil and 62.7 per cent with methyl aminolevulinate photodynamic therapy; imiquimod beat...
5-year OS 81.4% vs 76.1% (HR 0.70); benefit concentrated in p53-abnormal disease.
Clinically significant cancer 38% vs 26%.
OS 54.4 vs 35.0 months, HR 0.64.
Enzalutamide lengthened metastasis-free survival and, with longer follow-up, overall survival compared with placebo; approved in July 2018.
OS 13.6 vs 12.3 months, non-inferior (HR 0.92).
Complete response at 120 weeks 48 percent with rituximab-lenalidomide against 53 percent with rituximab-chemotherapy (p 0.13) and median progression-free survival 120.2 against 123...
ORR 56%; median OS 15 months.
Three-year disease-free survival 76.7 percent with three months against 77.1 percent with six (hazard ratio 1.006, 0.909 to 1.114, non-inferiority p = 0.012), with grade 2 or worse...
PFS 11.0 vs 5.7 months, HR 0.65 (PIK3CA-mutant).
PFS HR 0.30; 7-year OS 67.0% vs 46.5% (HR 0.55).
Prostate cancer deaths 71 of 347 with surgery against 110 of 348 with watchful waiting (relative risk 0.55, 95 percent confidence interval 0.41 to 0.74); number needed to treat 8.4...
Median androgen deprivation-free survival 21 months with metastasis-directed therapy against 13 months with surveillance (hazard ratio 0.60, 80 percent confidence interval 0.40 to...
9-year iDFS 83.3% vs 84.3%; non-inferior.
No superiority of carboplatin over docetaxel in unselected triple-negative disease; higher response to carboplatin in the germline BRCA1/2 subgroup (Nature Medicine 2018).
Pathological complete response 67% without anthracycline vs 68% with; 3-year event-free survival 93.5% vs 92.7%.
Freedom from locoregional relapse at five years 87 per cent with chemoradiotherapy against 83 per cent with radiotherapy alone (hazard ratio 0.84, 95 per cent confidence interval 0...
Invasive cancer incidence HR 0.96 (vitamin D), 1.03 (omega-3); no benefit on primary endpoints.
The publication year on key paper records.
Bensch F, van der Veen EL, Lub-de Hooge MN, et al. Nature Medicine.
Chun YS, Pawlik TM, Vauthey JN. Annals of Surgical Oncology.
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. Modern Pathology.
Makvandi M, Pantel A, Schwartz L, et al. Journal of Clinical Investigation.
Zhao WH, Liu J, Wang BY, et al. Journal of hematology & oncology.
Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al. EMBO molecular medicine.
Wilson ML, Fleming KA, Kuti MA, et al. The Lancet.
Alexander BM, Ba S, Berger MS, et al. Clinical Cancer Research.
Zammarchi F, Corbett S, Adams L, et al. Blood.
Loibl S, O'Shaughnessy J, Untch M, et al. The Lancet Oncology.
Allemani C, Matsuda T, Di Carlo V, et al. The Lancet.
Knaul FM, Farmer PE, Krakauer EL, et al. The Lancet.
Oxnard GR, Hu Y, Mileham KF, et al. JAMA Oncology.
Hu C, Hart SN, Polley EC, et al. JAMA.
Qian ZR, Rubinson DA, Nowak JA, et al. JAMA Oncology.
Schmid P, Adams S, Rugo HS, et al. New England Journal of Medicine.
Binnewies M, Roberts EW, Kersten K, et al. Nature Medicine.
Pandit-Taskar N, Zanzonico P, Staton KD, et al. Journal of Nuclear Medicine.
Rossi D, Spina V, Gaidano G. Blood.
Gandara DR, Paul SM, Kowanetz M, et al. Nature Medicine.
Bourgeois-Daigneault MC, Roy DG, Aitken AS, et al. Science Translational Medicine.
Bray F, Ferlay J, Soerjomataram I, et al. CA: A Cancer Journal for Clinicians.
Camidge DR, Kim HR, Ahn MJ, et al. New England Journal of Medicine.
Solheim TS, Laird BJA, Balstad TR, et al. BMJ supportive & palliative care.
Tutt A, Tovey H, Cheang MCU, et al. Nature Medicine.
Fader AN, Roque DM, Siegel E, et al. Journal of Clinical Oncology.
Cardoso F, Bartlett JMS, Slaets L, et al. Annals of Oncology.
Armand P, Engert A, Younes A, et al. Journal of Clinical Oncology.
Motzer RJ, Tannir NM, McDermott DF, et al. New England Journal of Medicine.
Bakhoum SF, Ngo B, Laughney AM, et al. Nature.
Kurtz DM, Scherer F, Jin MC, et al. Journal of Clinical Oncology.
Annala M, Vandekerkhove G, Khalaf D, et al. Cancer Discovery.
Loree JM, Pereira AAL, Lam M, et al. Clinical Cancer Research.
Aggarwal R, Huang J, Alumkal JJ, et al. Journal of Clinical Oncology.
Neyaz A, Husain N, Kumari S, et al. Histopathology.
Yaeger R, Chatila WK, Lipsyc MD, et al. Cancer Cell.
Dummer R, Ascierto PA, Gogas HJ, et al. The Lancet Oncology.
Fushimi C, Tada Y, Takahashi H, et al. Annals of Oncology.
Tawbi HA, Forsyth PA, Algazi A, et al. New England Journal of Medicine.
Kahles A, Lehmann KV, Toussaint NC, et al. Cancer Cell.
Abla O, Jacobsen E, Picarsic J, et al. Blood.
Fiolet T, Srour B, Sellem L, et al. BMJ.
Lancet JE, Uy GL, Cortes JE, et al. Journal of Clinical Oncology.
Schöffski P, Sufliarsky J, Gelderblom H, et al. The Lancet. Respiratory medicine.
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Journal of Clinical Oncology.
Gilligan AM, Alberts DS, Roe DJ, et al. The American journal of medicine.
Cohen JD, Li L, Wang Y, et al. Science.
Schultz KAP, Williams GM, Kamihara J, et al. Clinical Cancer Research.
Henricks LM, Lunenburg CATC, de Man FM, et al. The Lancet Oncology.
DiNardo CD, Stein EM, de Botton S, et al. New England Journal of Medicine.
Grothey A, Sobrero AF, Shields AF, et al. New England Journal of Medicine.
Connors JM, Jurczak W, Straus DJ, et al. New England Journal of Medicine.
Han B, Li K, Wang Q, et al. JAMA Oncology.
McNeil JJ, Nelson MR, Woods RL, et al. New England Journal of Medicine.
Arbour KC, Jordan E, Kim HR, et al. Clinical Cancer Research.
Hanai A, Ishiguro H, Sozu T, et al. JNCI: Journal of the National Cancer Institute.
Maude SL, Laetsch TW, Buechner J, et al. New England Journal of Medicine.
Sigismund S, Avanzato D, Lanzetti L. Molecular oncology.
Freites-Martinez A, Shapiro J, Chan D, et al. JAMA dermatology.
Traina TA, Miller K, Yardley DA, et al. Journal of Clinical Oncology.
Biondi A, Gandemer V, De Lorenzo P, et al. The Lancet Haematology.
European Study Group on Cystic Tumours of the Pancreas. Gut.
Fassnacht M, Dekkers OM, Else T, et al. European Journal of Endocrinology.
Raverot G, Burman P, McCormack A, et al. European journal of endocrinology.
Oktay K, Harvey BE, Partridge AH, et al. Journal of Clinical Oncology.
Adams TS, Cuello MA. International Journal of Gynecology & Obstetrics.
Horn L, Mansfield AS, Szczęsna A, et al. New England Journal of Medicine.
Soria JC, Ohe Y, Vansteenkiste J, et al. New England Journal of Medicine.
Grasso CS, Giannakis M, Wells DK, et al. Cancer Discovery.
Bielski CM, Zehir A, Penson AV, et al. Nature Genetics.
Wardell CP, Fujita M, Yamada T, et al. Journal of Hepatology.
Quigley DA, Dang HX, Zhao SG, et al. Cell.
Aung KL, Fischer SE, Denroche RE, et al. Clinical Cancer Research.
Huguet F, Chevret S, Leguay T, et al. Journal of Clinical Oncology.
Heining C, Horak P, Uhrig S, et al. Cancer Discovery.
Jones BA, Varambally S, Arend RC. Molecular Cancer Therapeutics.
Hu ZI, Shia J, Stadler ZK, et al. Clinical Cancer Research.
Wolff AC, Hammond MEH, Allison KH, et al. Journal of Clinical Oncology.
Mok TS, Cheng Y, Zhou X, et al. Journal of Clinical Oncology.
Pfeiffer A, Thalheimer FB, Hartmann S, et al. EMBO molecular medicine.
Zheng Y, Walsh T, Gulsuner S, et al. Journal of Clinical Oncology.
Lyman GH, Greenlee H, Bohlke K, et al. Journal of Clinical Oncology.
Herrera AF, Moskowitz AJ, Bartlett NL, et al. Blood.
Pages F, Mlecnik B, Marliot F, et al. Lancet.
Isaacsson Velho P, Silberstein JL, Markowski MC, et al. The Prostate.
Felsenstein M, Noe M, Masica DL, et al. Gut.
Eggermont AMM, Blank CU, Mandala M, et al. New England Journal of Medicine.
Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. New England Journal of Medicine.
Ramirez PT, Frumovitz M, Pareja R, et al. New England Journal of Medicine.
Drilon A, Laetsch TW, Kummar S, et al. New England Journal of Medicine.
Lear JT, Migden MR, Lewis KD, et al. Journal of the European Academy of Dermatology and Venereology.
Andricovich J, Perkail S, Kai Y, et al. Cancer Cell.
Kim YH, Bagot M, Pinter-Brown L, et al. The Lancet Oncology.
Sharma A, Kandlakunta H, Nagpal SJS, et al. Gastroenterology.
Rizvi H, Sanchez-Vega F, La K, et al. Journal of Clinical Oncology.
Seymour JF, Kipps TJ, Eichhorst B, et al. New England Journal of Medicine.
Hurvitz SA, Martin M, Symmans WF, et al. The Lancet Oncology.
Albrengues J, Shields MA, Ng D, et al. Science.
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. New England Journal of Medicine.
Ray-Coquard I, Morice P, Lorusso D, et al. Annals of Oncology.
Scher HI, Graf RP, Schreiber NA, et al. JAMA Oncology.
D'Angelo SP, Melchiori L, Merchant MS, et al. Cancer Discovery.
Kim HS, Park JW, Kim H, et al. Journal of Hepato-Biliary-Pancreatic Sciences.
Tiriac H, Belleau P, Engle DD, et al. Cancer Discovery.
Dummer R, Ascierto PA, Gogas HJ, et al. The Lancet Oncology.
Antonia SJ, Villegas A, Daniel D, et al. New England Journal of Medicine.
Cristescu R, Mogg R, Ayers M, et al. Science.
Tetzlaff MT, Messina JL, Stein JE, et al. Annals of Oncology.
Migden MR, Rischin D, Schmults CD, et al. New England Journal of Medicine.
Tsao MS, Kerr KM, Kockx M, et al. Journal of Thoracic Oncology.
Giaccone G, Kim C, Thompson J, et al. The Lancet Oncology.
Paz-Ares L, Luft A, Vicente D, et al. New England Journal of Medicine.
Patel KN, Angell TE, Babiarz J, et al. JAMA surgery.
Ishigami H, Fujiwara Y, Fukushima R, et al. Journal of Clinical Oncology.
Ghaffarizadeh A, Heiland R, Friedman SH, et al. PLoS computational biology.
de Boer SM, Powell ME, Mileshkin L, et al. The Lancet Oncology.
Mohile SG, Dale W, Somerfield MR, et al. Journal of Clinical Oncology.
Makohon-Moore AP, Matsukuma K, Zhang M, et al. Nature.
Kasivisvanathan V, Rannikko AS, Borghi M, et al. New England Journal of Medicine.
Wei D, Heus P, van de Wetering FT, et al. The Cochrane database of systematic reviews.
Conroy T, Hammel P, Hebbar M, et al. New England Journal of Medicine.
Islami F, Goding Sauer A, Miller KD, et al. CA: A Cancer Journal for Clinicians.
Lowery MA, Wong W, Jordan EJ, et al. JNCI: Journal of the National Cancer Institute.
Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Journal of Clinical Oncology.
Hussain M, Fizazi K, Saad F, et al. New England Journal of Medicine.
Parker CC, James ND, Brawley CD, et al. The Lancet.
Aguirre AJ, Nowak JA, Camarda ND, et al. Cancer Discovery.
Kudo M, Finn RS, Qin S, et al. The Lancet.
Morschhauser F, Fowler NH, Feugier P, et al. New England Journal of Medicine.
Teply BA, Wang H, Luber B, et al. The Lancet Oncology.
Lichtman AH, Lux EA, McQuade R, et al. Journal of pain and symptom management.
Robey RW, Pluchino KM, Hall MD, et al. Nature Reviews Cancer.
Ribas A, Wolchok JD. Science.
Canto MI, Almario JA, Schulick RD, et al. Gastroenterology.
Arbyn M, Smith SB, Temin S, Sultana F, Castle P. BMJ.
Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.
Brock PR, Maibach R, Childs M, et al. New England Journal of Medicine.
Casali PG, Abecassis N, Aro HT, et al. Annals of Oncology.
Moore K, Colombo N, Scambia G, et al. New England Journal of Medicine.
Martincorena I, Fowler JC, Wabik A, et al. Science.
Smith MR, Saad F, Chowdhury S, et al. New England Journal of Medicine.
Bill-Axelson A, Holmberg L, Garmo H, et al. New England Journal of Medicine.
Skoulidis F, Goldberg ME, Greenawalt DM, et al. Cancer Discovery.
Puleo F, Nicolle R, Blum Y, et al. Gastroenterology.
Loibl S, Weber KE, Timms KM, et al. Annals of Oncology.
Sparano JA, Gray RJ, Makower DF, et al. New England Journal of Medicine.
Litton JK, Rugo HS, Ettl J, et al. New England Journal of Medicine.
Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Journal of Clinical Oncology.
Hoadley KA, Yau C, Hinoue T, et al. (The Cancer Genome Atlas Network). Cell.
Tauriello DVF, Palomo-Ponce S, Stork D, et al. Nature.
Mariathasan S, Turley SJ, Nickles D, et al. Nature.
Herbst RS, Morgensztern D, Boshoff C. Nature.
Armenia J, Wankowicz SAM, Liu D, et al. Nature Genetics.
Bolouri H, Farrar JE, Triche T, et al. Nature Medicine.
Bakhoum SF, Cantley LC. Cell.
Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. American Journal of Cancer Research.
Thorsson V, Gibbs DL, Brown SD, et al. Immunity.
Miften M, Olch A, Mihailidis D, et al. Medical physics.
Hernandez I, Prasad V, Gellad WF. JAMA Oncology.
van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. The Lancet Oncology.
Dix DB, Seibel NL, Chi YY, et al. Journal of Clinical Oncology.
Shimelis H, LaDuca H, Hu C, et al. JNCI: Journal of the National Cancer Institute.
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. The Lancet Oncology.
Bareche Y, Venet D, Ignatiadis M, et al. Annals of Oncology.
Kaufman HL, Russell JS, Hamid O, et al. Journal for ImmunoTherapy of Cancer.
Lindeman NI, Cagle PT, Aisner DL, et al. Journal of Thoracic Oncology.
Gehl J, Sersa G, Matthiessen LW, et al. Acta oncologica.
Johnson SB, Park HS, Gross CP, Yu JB. JNCI: Journal of the National Cancer Institute.
US Preventive Services Task Force, Grossman DC, Curry SJ, et al. JAMA.
Diamond EL, Subbiah V, Lockhart AC, et al. JAMA Oncology.
Ren S, Wei GH, Liu D, et al. European Urology.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Pancreatic ductal adenocarcinoma. Median OS 54 months after resection.
Neuroendocrine and small-cell prostate cancer
Head and neck squamous cell carcinoma
ALK-positive non-small-cell lung cancer
Early-onset colorectal cancer (under 50)
Wilms tumour (nephroblastoma)
Acute promyelocytic leukaemia
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Acute lymphoblastic leukaemia. First approval based on an MRD endpoint (BLAST).
Cutaneous squamous cell carcinoma. EMPOWER-CSCC-1 (NEJM 2018).
Advanced melanoma (unresectable stage III and stage IV)
Brain metastases (secondary brain tumours)
Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma).
Non-small-cell lung cancer. STK11 and KEAP1 are tied to poor immunotherapy outcomes in KRAS-mutant disease; the College of American Pathologists, the International Association for...
BRAF V600-mutant melanoma
Anaplastic thyroid cancer. The first drug approval for this cancer.
Thyroid cancer
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
Hodgkin lymphoma
Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma). Brentuximab-CHP improves OS over CHOP; mogamulizumab approved for MF/Sézary (MAVORIC).
Relapsed and refractory acute lymphoblastic leukaemia in children
Metastatic triple-negative breast cancer
Advanced cutaneous squamous cell carcinoma
Melanoma
Inflammatory myofibroblastic tumour (IMT). Schöffski and colleagues, Lancet Respir Med: high response rate in ALK-positive IMT.
Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma. Temozolomide as first-line chemotherapy.
Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)
Ewing sarcoma
Chronic myeloid leukaemia, chronic phase
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Thymoma (WHO types A, AB, B1, B2 and B3)
Early cervical cancer and fertility-sparing surgery
Rosai-Dorfman-Destombes disease
Triple-negative breast cancer (TNBC). IMpassion130: atezolizumab + nab-paclitaxel improves PFS in PD-L1+ metastatic TNBC (approval later withdrawn).
EGFR-mutated non-small-cell lung cancer
Diffuse midline glioma, H3 K27-altered (including DIPG). Mount and Monje (Nature Medicine) show GD2 CAR-T clears tumours in mouse models.
Pancreatic ductal adenocarcinoma. Hu, 3,030 patients. Canto, 354 high-risk individuals over 16 years: 9 of 10 surveillance-detected cancers resectable.
FLT3-mutated acute myeloid leukaemia
Uterine sarcoma. Adjuvant chemotherapy for stage I LMS did not improve outcomes; observation is standard.
Paediatric high-grade glioma (excluding diffuse midline glioma). Grill and colleagues (JCO).
Pheochromocytoma and paraganglioma (PPGL). FDA, July 2018, for unresectable MIBG-positive PPGL; later discontinued commercially.
Metastatic pheochromocytoma and paraganglioma
Colorectal cancer
Extensive-stage small-cell lung cancer
Small-cell lung cancer
Waldenström macroglobulinaemia
Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)
Male breast cancer. Cardoso and colleagues (Ann Oncol 2018) characterise 1,483 men treated 1990 to 2010.
IDH1- and IDH2-mutated acute myeloid leukaemia
Acute myeloid leukaemia. Ivosidenib (IDH1) and gilteritinib (ADMIRAL) approved; venetoclax + HMA/LDAC gets accelerated approval for unfit AML.
Early HER2-positive breast cancer
HER2-positive breast cancer
Stage III melanoma (after surgery)
PD-L1-high non-small-cell lung cancer without a driver mutation
Early cervical cancer and fertility-sparing surgery
Cervical cancer. Practice reverses to open surgery within months.
KRAS wild-type pancreatic ductal adenocarcinoma
Salivary gland cancers
NTRK fusion-positive non-small-cell lung cancer
Salivary duct carcinoma
Neuroendocrine tumours
Neuroendocrine tumours
Pancreatic neuroendocrine tumours
Small intestinal neuroendocrine tumours
Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)
Primary myelofibrosis
Hairy cell leukaemia. First CD22 immunotoxin; withdrawn from the US market in 2023 for commercial reasons.
Relapsed or refractory chronic lymphocytic leukaemia
Adenosquamous carcinoma of the pancreas
Pancreatic ductal adenocarcinoma. Pancreatic protocol CT before biliary drainage, PET-CT for localised disease, enzyme replacement for unresectable disease, surveillance criteria f...
Clear cell renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
KRAS wild-type pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma. NRG1 fusions found in every KRAS wild-type tumour of a young-adult series (Heining), later put at about 1% of all pancreatic cancers (Philip 2022)...
Non-small-cell lung cancer
Triple-negative breast cancer (TNBC). OlympiAD and EMBRACA lead to olaparib and talazoparib approvals.
Merkel cell carcinoma
Vaginal cancer. Extended in practice to HPV-associated vaginal cancer.
Primary mediastinal (thymic) large B-cell lymphoma
Thymoma and thymic carcinoma
Thymic carcinoma
Skin cancer (all types). Five-year results of the 601-patient Dutch trial: tumour-free survival 80.5 per cent with imiquimod, 70.0 with fluorouracil and 62.7 with methyl aminolevul...
Endometrial cancer
p53-abnormal endometrial cancer, including uterine serous carcinoma
Prostate cancer
Localised prostate cancer, very low and low risk
Resectable pancreatic ductal adenocarcinoma
p53-abnormal endometrial cancer, including uterine serous carcinoma
Hepatocellular carcinoma
Advanced hepatocellular carcinoma (BCLC C)
Follicular lymphoma. Lenalidomide-rituximab matches chemo-immunotherapy first line.
Pancreatic acinar cell carcinoma
Hepatoblastoma. FDA approval of sodium thiosulfate (Pedmark) 2022.
Germ cell tumours of childhood and adolescence (extracranial and CNS). SIOPEL 6 (NEJM 2018) and ACCL0431 show reduced cisplatin ototoxicity; FDA approval 2022.
Ovarian cancer. Two years of first-line olaparib maintenance (PFS HR 0.30) and HIPEC at interval surgery (OS +12 months) both reported.
High-grade serous ovarian cancer
Platinum-sensitive ovarian cancer
Desmoid tumour. Gounder and colleagues, NEJM.
Non-metastatic castration-resistant prostate cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN). First CD123-targeted therapy and first drug approved for BPDCN.
HR-positive / HER2-negative breast cancer
High-risk early HR-positive breast cancer
Prostate cancer. Deep whole genomes of 101 metastases find the AR upstream enhancer amplified in 81% of men, invisible to exome panels; reanalysis of 1,013 exomes finds 97 driver g...
Colorectal cancer. Among people with a complete clinical response after chemoradiotherapy who kept their rectum, local regrowth reached 25.2 percent at two years, almost all in the...
Triple-negative breast cancer (TNBC). In 376 advanced patients carboplatin doubled the response rate in germline BRCA carriers while the Myriad HRD score and BRCA1 methylation pred...
Chronic myeloid leukaemia (CML). EURO-SKI: about half of patients stopping TKI stay in remission.
Cutaneous squamous cell carcinoma. 321 patients randomised; freedom from locoregional relapse at five years 87 against 83 per cent with weekly carboplatin added, hazard ratio 0.84.
Prostate cancer. SPCG-4 at 29 years: surgery cut prostate cancer death by 45 percent in clinically detected disease and added a mean 2.9 years of life.
Breast cancer (all types). Used for all breast tumours diagnosed after 1 January 2018. The Royal College of Pathologists reprints it and advises against substituting the American A...
Acute myeloid leukaemia in older or unfit patients
Colorectal cancer. Mice with all four main colorectal mutations reproduce human microsatellite-stable disease and answer checkpoint blockade only once TGF-beta is inhibited; across...
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
New York, NY
Rehovot
New Haven, CT
New York, NY
Mumbai
Paris
San Diego, CA
New York, NY
Nanjing
Irvine, CA
Burlingame, CA
Berlin
Shanghai
The funding rounds on company records, each with the source that states the figure.
$2m. Led by Brooklyn Bridge Ventures with angel investors
$40m. Led by ARTIS Ventures; company launched as a majority-owned subsidiary of fusion company TAE Technologies
The founded year on journal records.
American Association for the Advancement of Science (Science Partner Journals)
Wiley
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
American Journal of Nuclear Medicine and Molecular Imaging
The Lancet Oncology
Blood Advances
Lancet Oncology
Nature Reviews Cancer
Modern Pathology
British Journal of Cancer
Annals of Oncology
Cancer
Cancer Immunology Research
Journal of Hematology & Oncology
Journal of Cancer Policy
Eur J Cancer
Annals of Oncology
Journal of Clinical Oncology
Lancet Oncology
NEJM
NEJM
Journal of Cancer Research and Clinical Oncology
Ann Surg
PLOS ONE
NEJM
JAMA Oncology
JAMA Oncology
JAMA Oncology
NEJM
The Lancet Oncology
Science
Blood
Blood
JAMA Oncology
NEJM
NEJM
The Lancet Oncology
Journal of Global Oncology
Science
Lancet Oncology
Nature Reviews Clinical Oncology
Lancet Oncol
Nature Medicine
Nature Reviews Clinical Oncology
Journal of Clinical Oncology
Clinical Cancer Research
Gynecologic Oncology
NEJM
Cell
Nature Genetics
Leukemia
Journal for ImmunoTherapy of Cancer
JCO
International Journal of Radiation Oncology*Biology*Physics
NEJM
Lancet Oncology
Science
Cell
Nature
Science Translational Medicine
NEJM
NEJM
European Journal of Vascular and Endovascular Surgery
JAMA
JAMA
JAMA
JAMA
Haematologica
New England Journal of Medicine
Acta Anaesthesiologica Scandinavica
Lancet Oncology
Science Translational Medicine
Eur Respir J
Psychooncology
Nature Reviews Cancer
Cancer Science
N Engl J Med
NEJM
Nature
Lancet Oncology
New England Journal of Medicine
Lancet Oncology
ESMO Open
Lancet
Science
Science
European Urology Oncology
Radiother Oncol
Lung Cancer
NEJM
New England Journal of Medicine
NEJM
NEJM
Eur J Neurol
NEJM
Virchows Archiv
Clinical Cancer Research
Genetics in Medicine
Lancet Oncology
Ann Surg
Lancet
New England Journal of Medicine
Lancet
Gastroenterology
Clinical Oncology
New England Journal of Medicine
NEJM
Cancer Immunology Research
Lancet
NEJM
New England Journal of Medicine
NEJM
Nature Medicine
The Lancet Oncology
Annals of Surgical Oncology
Thyroid
The Lancet Oncology
Nature Medicine
New England Journal of Medicine
NEJM
Blood Cancer Journal
Journal of Clinical Oncology
Cancers (Basel)
NEJM
Lancet Oncology
Journal of Molecular Biology
Journal of Global Oncology
Scandinavian Journal of Surgery
JCO
Nature Communications
Journal of Clinical Oncology
Clinical Breast Cancer
Cancer Immunology Research
Oncotarget
Breast Cancer Research and Treatment
Lancet Oncology
British Journal of Haematology
Radiology and Oncology
Clinical Lung Cancer
JNCI: Journal of the National Cancer Institute
Science
Journal of Clinical Oncology
Lancet Oncology
New England Journal of Medicine
Journal of Clinical Investigation
The Lancet Oncology
Lancet Oncology
Radiotherapy and Oncology
Proceedings of the National Academy of Sciences
Blood
Blood
NEJM
Nature Reviews Clinical Oncology
NEJM
Molecular Cancer
NEJM
Cancer
Cell
Am J Physiol Gastrointest Liver Physiol
JCO
Lancet Oncology
Science Immunology
Journal of Experimental & Clinical Cancer Research
European Journal of Cancer
Health and Quality of Life Outcomes
Annals of Oncology
NEJM
Cancer Immunology Research